Skip to main content
SpringerLink
Log in

Effect of Three Nonpeptide Cholecystokinin Antagonists on Human Isolated Gallbladder

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Cholecystokinin is the most important stimulant of postprandial gallbladder contraction, and a regulator of gallbladder fasting tone. The aim of this study was to evaluate the effect of dexloxiglumide on isolated human gallbladder contraction induced by cholecystokinin–octapeptide and to compare this effect to that of lorglumide and amiglumide, two glutaramic acid analogs of dexloxiglumide. The negative logarithms of the antagonist dissociation constant (pKB) values were 7.00 ± 0.14, 6.95 ± 0.11, and 6.71 ± 0.10 for lorglumide, dexloxiglumide, and amiglumide, respectively. Dexloxiglumide produced a concentration-dependent rightward shift of the cholecystokinin–octapeptide curve, without affecting its maximal response. A similar effect was obtained both with lorglumide and amiglumide. Moreover, the slopes for the three antagonists did not differ significantly from unity. These data show that the three molecules have a potent antagonistic effect, of a competitive nature, on gallbladder cholecystokinin type 1 receptors. It may be concluded that dexloxiglumide, lorglumide, and amiglumide exhibit a promising therapeutic profile for biliary colic and other gastrointestinal disorders in which CCK1 receptors play important physiological roles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Watson S, Abbot A: Receptor nomenclature supplement. Trends Pharmacol Sci 11 (suppl):1–30, 1990

    Google Scholar 

  2. Crawley JN, Corwin6RL: Biological actions of cholecystokinin. Peptides 15:731–755, 1994

    Google Scholar 

  3. Hahne WF, Jensen RT, Lemp GF, Gardner JD: Proglumide and benzotrip: Members of a different class of cholecystokinin receptor antagonist. Proc Natl Acad Sci USA 78:6304–6308, 1981

    Google Scholar 

  4. Makovec F, Chistè R, Bani M, Chistè R, Revel L, Setnikar I, Rovati AL: New glutamic and aspartic derivatives with potent CCK-antagonistic activity. Eur J Med Chem 21:9–20, 1986

    Google Scholar 

  5. Makovec F, Bani M, Chistè R, Revel L, Rovati LC, Rovati LA: Differentiation of central and peripheral cholecystokinin receptors by new glutaramic acid derivatives with cholecystokinin-antagonistic activity. Arzneim-Forsch 36:98–102, 1986

    Google Scholar 

  6. Setnikar I, Bani M, Cereda R, Chistè R, Makovec F, Pacini MA, Revel L, Rovati LC, Rovati LA: Pharmacological characterization of a new potent and specific non polypeptidic cholecystokinin antagonist. Arzneim-Forsch 37:703–707, 1987

    Google Scholar 

  7. Makovec F, Chistè R., Peris W, Rovati L: Derivatives of (R)-5–penthylamino-5–oxopentanoic acid with anticholecystokinin activity. European Patent No. 344184, 1988

  8. Scarpignato C, Kisfalvi I, D'Amato M, Varga G: Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: Evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther 10:411–419, 1996

    Google Scholar 

  9. Varga G, Kisfalvi K, Pelosini I, D'Amato M, Scarpignato C: Different actions of CCK on pancreatic and gastric growth in the rat: Effect of CCKA receptor blockade. Br J Pharmacol 124:435–440, 1998

    Google Scholar 

  10. Varga G, Kisfalvi K, D'Amato M, Scarpignato C: Effect of a new CCK-A receptor antagonist, dexloxiglumide, on the exocrine pancreas in the rat. J Physiol 91:257–264, 1997

    Google Scholar 

  11. Liddle RA, Gertz BJ, Kanayama S, Beccaria L, Coker LD, Turnbull TA, Morita ET: Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in human. Implications for the physiology of CCK. J Clin Invest 84:1220–1225, 1989

    Google Scholar 

  12. Konturek JW, Konturek SJ, A Kurek A, Bogdal J, Oleksy J, Rovati L: CCK receptor antagonism by loxiglumide and gallbladder contractions response to cholecystokinin, sham feeding and ordinary feeding in man. Gut 30:1136–1142, 1989

    Google Scholar 

  13. Revel L, Mennuni L, Garofalo P, Makovec F: CR 2945: A novel CCKB receptor antagonist with anxiolytic-like activity. Behav Pharmacol 9:183–194, 1998

    Google Scholar 

  14. Lennon F, Feeley TM, Clanacan AS, Scott GV: Effects of histamine receptors stimulation on diseased gallbladder and cystic duct. Gastroenterology 87:257–262, 1984

    Google Scholar 

  15. Messa C, Maselli MA, Cavallini A, Caruso ML, Pezzolla F, Di Leo A: Sex steroid hormone receptors and human gallbladder motility in vitro. Digestion 46:214–219, 1990

    Google Scholar 

  16. Arunlakshana O, Shild HO: Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14:48–58, 1959

    Google Scholar 

  17. Kenakin TP: Pharmacologic Analysis of Drug-Receptor Interaction. Raven Press, New York, 1987

    Google Scholar 

  18. Bitar KN, Maklouf GM: Receptors on smooth muscle cells: characterization by contraction and specific antagonists. Am J Physiol 242:G400–G407, 1982

    Google Scholar 

  19. Revel L, Makovec F, Castaner J: Dexloxiglumide. Drugs Future 24(7):725–728, 1999

    Google Scholar 

  20. Meier R, Beglinger C, Giacovelli G, D'Amato M: Effect of the CCK-A receptor antagonist Dexloxiglumide on postprandial gallbladder emptying and colonic transit time in healthy volunteers. Gastroenterology 106:A538, 1994

    Google Scholar 

  21. Niderau C, Heintges6T, Rovati LC, Strohmeyer G: Effects of Loxiglumide on gallbladder emptying in healthy volunteers. Gastroenterology 97:1331–1336, 1989

    Google Scholar 

  22. Lieverse RJ, Jansen JBM, Jebbink MCW, Masclee AAM, Rovati LC, Lamers CBHW: Effects of somatostatin and loxiglumide on gallbladder motility. Eur J Clin Pharmacol 47:489–492, 1995

    Google Scholar 

  23. Makovec F, Bani M, Cereda R, Chistè R, Pacini6MA, Revel L, Rovati LA, Rovati LC: Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneim-Forsch/Drug Res 37:1265–1268, 1987

    Google Scholar 

  24. D'Amato M, Stamford IF, Bennet A: Studies of three nonpeptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea pig ileum. Br J Pharmacol 102:391–395, 1991

    Google Scholar 

  25. Makovec F, Mennuni L, Peris W, Revel L, Rovati6LC: Biological properties of (R)-4–benzamido-5–oxopentanoic basic derivatives as CCK-antagonists. Bioorg and Med Chem Lett 36(5):861–866, 1993

    Google Scholar 

  26. Gully D, Frehel D, Marcy C, Spinazze A, Lespy L, Neliat G, Maffrand JP, LeFur G: Peripheral biological activity of SR 27897: A new potent nonpeptide antagonist of CCKA receptor. Eur J Pharmacol 232:13–19, 1993

    Google Scholar 

  27. Chang RSL, Lotti VJ, Cheng TB, Kunel KA: Characterization of the binding of [3H](±) L364,718: A new potent nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. Mol Pharmacol 30:212–217, 1986

    Google Scholar 

  28. Ito H, Sogabe H, Nakarai T, Sato Y, Tomoi M, Kadowaki M, Matsuo M, Tokoro K, Yoshida K: Pharmacological profile of FK 480, a novel cholecystokinin type-A receptor antagonist: Comparison to Loxiglumide. J Pharmacol Exp Ther 268:571, 1994

    Google Scholar 

  29. Hull R, Shenkley NP, Harper EA, Gerskowitch VP and Black JW: 2–Naphthalenesulphonyl L-aspartyl-(2–phenethylamide) (2–NAP)–a selective cholecystokinin CCKA-receptor antagonist. Br J Pharmacol 108:734–740, 1993

    Google Scholar 

  30. Beglinger C, Dill S, Meyer B, Werth B, Adler G: Treatment of biliary colic with loxiglumide. Lancet 2(8655):167, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Experimental Pathophysiology and Pharmacology Laboratory, Scientific Institute of Gastroenterology “S. de Bellis,”, Castellana Grotte, Bari

    M.A. Maselli & A.L. Piepoli

  2. Surgery Department, Scientific Institute of Gastroenterology “S. de Bellis,”, Castellana Grotte, Bari

    F. Pezzolla & D. Lorusso

  3. Epidemiology and Biostatistic Laboratory, Scientific Institute of Gastroenterology “S. de Bellis,”, Castellana Grotte, Bari

    V. Guerra

  4. Pathology Department, Scientific Institute of Gastroenterology “S. de Bellis,”, Castellana Grotte, Bari

    M.L. Caruso

  5. Pharmacology and Organic Chemistry Department, Rotta Research Laboratorium S.p.A, Monza, Milan, Italy

    L. Mennuni & F. Makovec

Authors
  1. M.A. Maselli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A.L. Piepoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Pezzolla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Guerra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M.L. Caruso
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Mennuni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Lorusso
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Makovec
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maselli, M., Piepoli, A., Pezzolla, F. et al. Effect of Three Nonpeptide Cholecystokinin Antagonists on Human Isolated Gallbladder. Dig Dis Sci 46, 2773–2778 (2001). https://doi.org/10.1023/A:1012748017709

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012748017709

Search

Navigation